Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6314140 | 0.82 | DHFR (0.45) | ESR1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL10763455 | 0.81 | ESR1 (0.52) | ESR1TSHRACHEGAAALDH1A1 | |
| SCHEMBL11204879 | 0.78 | ESR1 (0.45) | ESR1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL5610691 | 0.78 | ESR1 (0.40) | ESR1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL5609645 | 0.76 | CA12 (0.42) | ALDH1A1PPARGCDC25ACDC25BHPGD | |
| SCHEMBL4537404 | 0.76 | ESR1 (0.41) | ESR1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL7647280 | 0.76 | ESR1 (0.41) | ESR1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL30169568 | 0.75 | ACHE (0.64) | NPC1RAB9ASMN1; SMN2TSHRACHE | |
| SCHEMBL197690 | 0.75 | ACHE (0.64) | NPC1RAB9ASMN1; SMN2TSHRACHE | |
| SCHEMBL30354037 | 0.75 | ACHE (0.64) | NPC1RAB9ASMN1; SMN2TSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| EP-1354602-A1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | Sankyo Company, Limited (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | ESR1 775/4885NPC1 2139/4885RAB9A 2079/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | ESR1 775/4885NPC1 2139/4885RAB9A 2079/4885 |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | ESR1 2451/4885NPC1 981/4885RAB9A 3117/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | ESR1 2451/4885NPC1 981/4885RAB9A 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.